| Identification | Back Directory | [Name]
2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- | [CAS]
1397683-26-9 | [Synonyms]
BACE1-IN-13
2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- | [Molecular Formula]
C20H17FN8O2 | [MOL File]
1397683-26-9.mol | [Molecular Weight]
420.4 |
| Hazard Information | Back Directory | [Uses]
BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC50 = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models[1]. | [References]
[1] Peschiulli A, et al. A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. ACS Med Chem Lett. 2021 Dec 1;13(1):76-83. DOI:10.1021/acsmedchemlett.1c00445 |
|
|